Reply

Affiliations

¹ Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
² Institute for Technology Assessment, Liver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
³ Harvard Medical School, Boston, Massachusetts; Liver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, Massachusetts.

Comment

Sumeyye Samur et al. Clin Gastroenterol Hepatol. 2017 Dec.

. 2017 Dec;15(12):1981.

doi: 10.1016/j.cgh.2017.08.030. Epub 2017 Aug 31.

¹ Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
² Institute for Technology Assessment, Liver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
³ Harvard Medical School, Boston, Massachusetts; Liver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, Massachusetts.

No abstract available

Comment on

Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals.
Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, Hur C, Donnell DMS, Chung RT, Chhatwal J. Samur S, et al. Clin Gastroenterol Hepatol. 2018 Jan;16(1):115-122.e10. doi: 10.1016/j.cgh.2017.06.024. Epub 2017 Jun 17. Clin Gastroenterol Hepatol. 2018. PMID: 28634131 Free PMC article.
More Sensitivity Analysis of Share 35, Human Immunodeficiency Virus Co-infection, Delist, Hospital Cost on Cost Effectiveness of Direct-Acting Antiviral Agents for Liver Transplant Hepatitis C Virus Patients.
Liu X, Shin HP, Yoo JW. Liu X, et al. Clin Gastroenterol Hepatol. 2017 Dec;15(12):1979-1981. doi: 10.1016/j.cgh.2017.07.043. Epub 2017 Aug 4. Clin Gastroenterol Hepatol. 2017. PMID: 28826914 No abstract available.